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ABSTRACT
Objective: The main objective was to develop nanosuspension of glyburide (GLY) by quasi emulsification solvent diffusion method and to enhance 
dissolution and bioavailability characteristics of the drug GLY, an antidiabetic drug which belongs to Biopharmaceutical Classification System-II 
category.
Results: From these studies, it was confirmed that drugs and excipients chosen were compatible with each other. GLY-8 was the best formulation 
with a particle size of 85–96 nm with 168.7°C melting point, freely soluble in phosphate buffer pH 7.4, 93.53% drug entrapment, and 90.26±1 mV of 
zeta potential. This formulation shows percentage drug release of 99.85% in 24 h. In vivo pharmacokinetic study for optimized formulation (GLY -8) 
suggested that there was no reaction with the rat plasma. From the results, it was shown that Cmax and Tmax were found to be 0.604±0.03 μg/ml 
and 2±1.01 h, respectively. The values of t1/2 (h), area under the curve (AUC) (0-t), and AUC (0-∞) were found to be 10.04 h, 2.562±0.41 μg.h/ml, and 
2.147±0.45 μg.h/ml, respectively.
Conclusion: Based on the results obtained, oral administration of nanosuspension could not only provide the better absorption of poorly water 
soluble drugs but may also reduce toxicity and provide a new tool in drug delivery system.
Keywords: Glyburide, Scanning electron microscopy studies, In vitro drug release, In vivo pharmacokinetic evaluation, Dissolution and bioavailability 
enhancement.
INTRODUCTION
In the drug discovery and development, poor water solubility is regarded 
as wide problem. More than 40% of drugs are poorly soluble in water, so 
they show problems in formulating them in conventional dosage forms. 
This problem is complex for Class II drugs which are poorly soluble in 
aqueous and organic media. Nanosuspension preparation is preferred 
for compounds that are insoluble in water (but are soluble in oil) with 
high log p value. Various approaches are there to resolve problems of low 
solubility and low bioavailability such as micronization, cosolvency, oily 
solution, and salt formation, and some other techniques are liposomes, 
emulsions, microemulsion, solid dispersion, and β-cyclodextrins inclusion 
complex. In these cases, nanosuspensions are preferred. It is most suitable 
for the compounds with high log p value, high melting point, and high 
dose. Nanosuspensions can be used to enhance the solubility of drugs that 
are poorly soluble in aqueous as well as lipid media. As a result, the rate 
of flooding of the active compound increases and the maximum plasma 
level is reached faster (e.g., oral or intravenous administration of the 
nanosuspension). This is one of the unique advantages that it has over other 
approaches for enhancing solubility. It is useful for molecules with poor 
solubility, poor permeability, or both, which poses a significant challenge for 
the formulators [1]. Glibenclamide which is also known as glyburide (GLY) 
belongs to second-generation sulfonylurea. It is majorly used to treat non-
insulin-dependent diabetes mellitus and administered orally [2]. GLY has 
been classified as the Biopharmaceutical Classification System (BCS) class-II 
drug due to its low aqueous solubility, with bioavailability of 100% and huge 
permeability. The solubility of GLY in gastrointestinal fluids and pH in the 
gastrointestinal tract impact on its in vivo dissolution. A lot of approaches 
have been made to optimize in vivo dissolution and bioavailability. However, 
to predict the in vivo performance of a dosage form, it is necessary to have 
an in vitro–in vivo correlation studies. The main objective of this study was 
to develop nanosuspension of GLY by quasi emulsification solvent diffusion 
method and also to enhance dissolution and bioavailability. This manuscript 
includes 12 formulations of GLY which were prepared with three different 
polymers such as polyvinyl alcohol (PVA), hydroxypropyl methyl cellulose 
(HPMC), and Eduragit (EDG) with a stabilizer, i.e. poloxamer 407 with 
formulation codes from GLY-1 to GLY-12. The best formulation had been 
identified and further subjected to both in vitro and in vivo studies [3-5]. 




GLY drug sample was procured from Hetero Drugs, Hyderabad. HPMC 
was procured from Yucca Enterprises, Mumbai. PVA was brought from 
Yarrow Chem Products., Mumbai. EDG RL 100 was procured from Yucca 
Enterprises, Mumbai. Poloxamer 407 was procured from SD Fine Chem, 
Hyderabad. All other chemicals and reagents utilized in the study were 
with the analytical grade.
Analytical method development
Determination of λ max
Ultraviolet (UV) spectrum of GLY was carried out in phosphate buffer 
pH 7.4. 10 mg of GLY was weighed accurately and transferred to a 10 ml 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i4.31657
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Methods:  In  this  work,  nanoparticles  were  prepared  using  polyvinyl  alcohol,  hydroxypropyl  methyl  cellulose,  and  Eudragit  RL100.  Twelve 
formulations of GLY (GLY-1–GLY-12) were formulated using the excipients at various compositions. Drug and excipient compatibility studies were 
conducted  using  Fourier  transform  infrared  and  differential  scanning  calorimeter.  The  prepared  nanosuspension  was  analyzed  using  scanning 
electron microscopy for surface of the particle analysis, melting point, solubility, particle charge zeta (mv), percentage drug entrapment efficiency (%), 
and in vitro drug release. The optimized formulations of nanosuspension were further studied for in vivo pharmacokinetic evaluation. Reverse-phase 
high-performance liquid chromatography method was developed, validated, and used for the study of these formulations in rat plasma.
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volumetric flask. The solution of 10 µg/ml was kept in a fused silica 
cuvette. UV spectrum was recorded in the range of 200–800 nm by 
Shimadzu double-beam UV-visible spectrophotometer against blank 
buffer solution pH 7.4. The wavelength for maximum absorbance was 
recorded [6].
Preparation of stock solution
Accurately weighed 10 mg of GLY was dissolved in 100 ml of phosphate 
buffer pH 7.4 to get a concentration of 100 µg/ml.
Preparation of standard solution
From the above stock solution, 1, 2, 3, 4, and 5 ml were transferred to 
a 10 ml volumetric flask and volume was made up to the mark with 
phosphate buffer pH 7.4. The final concentrations of 10, 20, 30, 40, and 
50 µg/ml were obtained. Absorbance of the above standard solutions 
was determined in a UV-visible spectrophotometer and calibration 
curve (CC) was constructed between concentration and absorbance [7].
Fourier transform infrared (FTIR) spectroscopic analysis
FTIR spectra of GLY were studied. GLY and KBR were mixed and 
compressed into a pellet in the ratio of 1:100 in a motorized pellet press 
(Ki Maya Engineers, India) at 10:12 tons of pressure. The pressed pellet 
was scanned in FTIR spectrophotometer. The FTIR spectrum of GLY was 
compared with the standard pharmacopoeial spectrum of GLY [8].
Preparation of GLY nanosuspension
GLY nanosuspensions were prepared by quasi emulsification solvent 
diffusion method. G LY (30 mg), PVP, HPMC, and EDG RL100 (0.5, 1.0, 
1.5, and 2%) were codissolved in 15 ml of methanol. The solution was 
slowly injected with a syringe containing thin Teflon tube into 35 ml 
water containing poloxamer 407. It was maintained at low temperature 
in ice bath to protect from sun light. During injection, the mixture was 
stirred well by a high-speed homogenizer at a speed of 5500 rpm. The 
solution immediately turned into pseudo emulsion in the external 
aqueous phase. The counter diffusion of methanol and water out of and 
into the emulsion microdroplets, respectively, results into the formation 
of nanosuspension. Formulation was prepared with varying polymer 
ratio. 12 formulations of GLY were prepared with three different 
polymers such as PVA, HPMC, and EDG with a stabilizer, i.e., poloxamer 
407 with formulation codes from GLY-1 to GLY-12. Table 1 gives the 
formulation of GLY nanosuspensions [9].
Physicochemical evaluation of drugs
Color and appearance
The color and appearance of drug were observed and recorded.
Melting point
The melting point of GLY was determined by open capillary method. The 
melting point was determined by introducing small amount of substance 
in the capillary which was then attached to graduated thermometer. 
Later, constant heat was applied with the assembly suspended in the 
paraffin bath. The drug sample was tested at the temperature ranging 
between 200 and 250°C. The temperature required to melt drug was 
noted.
Solubility studies
Solubility studies were done by adding 100 mg of drug in increments 
to 10 ml of different buffer solutions. The conical flasks with 250 ml of 
water were kept on a shaker water bath until saturation occurred. The 
conical flasks were kept for 5 h at ambient temperature. The samples 
were centrifuged and filtered and the filtrates were analyzed by UV-
visible spectrophotometer [10].
Evaluation of GLY nanosuspension
Size analysis
Scanning electron microscopy (SEM) is a method for high-resolution 
surface imaging. The SEM uses an electron beam for surface imaging. The 
advantages of SEM over light microscopy are greater magnification and 
much larger depth of field. Different elements and surface topographies 
emit different quantities of electrons, due to which the contrast in a 
SEM micrograph (picture) is representative of the surface topography 
and distribution of elemental composition on the surface [11].
Zeta potential of the drug
Zeta potential measurements were run at 25°C with an electric 
field strength of 23 V/m, using Zetasizer (Nano ZS 90, Malvern 
Instruments, UK). To determine the zeta potential, samples of drug 
nanosuspensions were diluted and placed in electrophoretic cell. The 
zeta potential was calculated as described by Helmholtz–Smoluchowski 
equation. The formulation of GLY with PVA, HPCM, and EDG RL 100 
with a stabilizer poloxamer 407 (Pluronic F127) was done. After 
formulating the suspension or nanosuspension, the zeta potential was 
determined to know the stability of the nanosuspension. Zeta potential 
is very important as it measures stability. Hence, all formulations were 
determined with zeta potential and recorded [12].
Drug content
= Obtainedamount of drug%Drug content
Theoratical amount of drug
A weighed amount of each preparation was dissolved in the required 
amount of methanol and diluted suitably in phosphate buffer of pH 7.4. 
Spectrophotometrically, drug content was determined at required 
wavelength. Calculation was done using the following formula [13].
Percentage entrapment efficiency
To determine percentage entrapment, around 2 ml of each formulation 
was taken in c (10 ml) and was centrifuged in centrifuge machine at 
2000–3000 rpm for 4 h. The supernatant layer was filtered through 
Whatman filter paper no: 41 and diluted with phosphate buffer 
Table 1: Formulation of GLY nanosuspensions using emulsification solvent diffusion method
Formula (mg) GLY PVA (%) HPMC (%) EDG Poloxamer (mg) Distilled water (ml)
GLY-1 30 0.5 – – 200 50
GLY-2 30 1.0 200 50
GLY-3 30 1.5 200 50
GLY-4 30 2.0 200 50
GLY-5 30 0.5 200 50
GLY-6 30 1.0 200 50
GLY-7 30 1.5 200 50
GLY-8 30 2.0 200 50
GLY-9 30 0.5 200 50
GLY-10 30 1.0 200 50
GLY-11 30 1.5 200 50
GLY-12 30 2.0 200 50
GLY: Glyburide, PVA: Polyvinyl alcohol, HPMC: Hydroxypropyl methyl cellulose, EDG: Eudragit
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pH 7.4. The resultant solutions were analyzed at a wavelength of nm 
of respective drug using UV double-beam spectrophotometer. These 
readings were taken for 3 times and the result was calculated [14]. 
The percentage entrapment efficiency was calculated according to the 
following equation or formula:
EE= (Total drug content – free drug content/Total drug content) × 100
Differential scanning calorimetry (DSC)
GLY thermal behavior was assessed by carrying out thermal analysis 
by DSC (DSC-Hitachi 7020). The samples (8–10 mg) were carefully 
transferred and heated in a crimped aluminum pan for accurate results. 
The samples were heated from 100 to 600°C at the rate of 10°C/min. 
A physical mixture of GLY with polymers (PVA, HPMC, and EDG) in the 
ratio of 1:1 was assessed by carrying out thermal analysis. Thermogram 
for drug and polymer mixture was taken by using DSC (Mettler DSC 1 
star system, Mettler-Toledo, Switzerland) [15].
In vitro drug release studies
In vitro drug release of the nanosuspension was carried out using USP 
dissolution apparatus type 2 (paddle type). 5 ml of nanosuspension 
was taken in a dialysis membrane consisting of spectra or membrane 
(cutoff: 1200 Da). This dialysis system was tied to paddle and 
dissolution medium with phosphate buffer pH 7.4. Dissolution was 
carried in triplicate for 10 h at 37±10°C temperature and 50 rpm. At 
regular intervals of time, 1 ml of sample from the external medium was 
taken and replaced with fresh phosphate buffer and all the samples 
were analyzed at nm of respective drug using U.V spectrophotometer. 
GLY nanosuspensions were prepared by quasi emulsification method 
which were analysed by in vitro drug dissolution method  [7,11].
Mathematical dissolution model for GLY nanosuspension 
formulations
Various mathematical dissolution models such as Higuchi, Krosmeyer–
Peppas, and first order were applied for GLY nanosuspension to 
evaluate the release kinetics of GLY nanosuspension.
In vivo studies
Bioavailability studies in Wistar rats
Male Wistar rats weighing about 200±20 g were supplied by the 
Experimental Animal Center of Local Vendor, and animal experiment 
was evaluated and approved by the Institution of Animal Ethics 
Committee (1423/PO/a/04/CPCSEA/104/2018). Rats were randomly 
divided into two groups with six animals each and were caged at least 
for 3 days before the study. They had free access to both food and 
water. Food was withdrawn 12 h before start of the study. An optimized 
formulation of nanosuspension was administrated orally to rats [16].
RESULTS
Analytical method for GLY
Determination of λmax
UV spectra of GLY in phosphate buffer pH 7.4 were determined by 
double beam UV-Visible spectrophotometer and found to be at 229 nm. 
Fig. 1 shows the λmax curve of GLY.
CC and physical properties of GLY
CC of GLY was constructed by determining the absorbance of GLY 
at 229 nm. It was observed that GLY showed good linearity over 
the concentration range of 25–150 µg/ml. Table 2 and Fig. 2 show 
calibration and linearity curve data of GLY, respectively. The color of GLY 
was white and crystalline in appearance Table 3.
Drug-excipient compatibility studies
Drug and excipient compatibility studies were performed using FTIR 
spectrophotometer and DSC, and no marked incompatibilities were 
found which was shown in Fig 3 and 4.
Physical properties of GLY nanosuspension
Melting point
Capillary tube method was used to determine melting point and was 
found to be 168.7°C, GLY. This value is the same as that of the literature 
citation shown in Table 4.
Table 2: CC data of GLY in phosphate buffer pH 7.4







GLY: Glyburide, CC: Calibration curve
Table 3: Physical properties of drug




Fig. 1: λmax curve of glyburide in phosphate buffer pH 7.4
Table 4: Melting point determination of drug
Drug name GLY°C
Reported melting point 165–171
Observed Melting Point 168.7
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Solubility studies
Table 5 shows the results of solubility studies according to pharmacopeia 
limits
Evaluation of GLY nanosuspension
SEM
SEM of optimized formula (GLY-8) is shown in Fig. 5 and SEM analysis of 
different formulations is described in Table 6.
DSC
DSC thermograms of pure GLY and GLY plus polymer blend were 
mentioned in Figs. 6 and 7.
In vitro drug release studies: Table 7 and Fig 8 showed the percentage 
cumulative drug release of various GLY nanosuspensions.
Mathematical dissolution model for GLY nanosuspension 
formulations
Various mathematical dissolution models such as Higuchi, Korsmeyer-Peppas, 
and first order were applied for GLY nanosuspension to evaluate the release 
kinetics of GLY nanosuspension. Table 8 and Figs. 9-11 give the data and plots 
of Higuchi, Krosmeyer–Peppas, and first order, respectively.
Fig. 2: Calibration curve of glyburide in phosphate buffer pH 7.4
Fig. 3: Fourier transformed infrared spectrum of glyburide
Table 5: Solubility studies
Medium mg/100 ml
Water Insoluble
Phosphate buffer pH (6.8) Very slightly soluble
Methanol Soluble
Chloroform (CHCL3) Soluble
Table 6: Evaluation studies of particle size (nm), drug content, % drug entrapped, and zeta potential (mV) for GLY nanosuspension
S. No Formulation Particle size Drug content % Drug entrapped Zeta potential 
1 GLY-1 198–225 78.62±0.24 77.11 61.58±1
2 GLY-2 196–210 96.38±0.84 75.90 65.20±1
3 GLY-3 215–230 87.47±1.41 71.89 64.15±2
4 GLY-4 241–236 75.23±0.59 80.75 70.11±2
5 GLY-5 152–163 79.66±0.45 89.48 79.55±1
6 GLY-6 172–189 92.84±0.57 88.80 81.48±2
7 GLY-7 111–125 88.45±1.22 84.76 85.22±1
8 GLY-8 85–96 98.93±0.62 93.53 90.26±1
9 GLY-9 325–315 78.21±0.47 57.52 35.10±2
10 GLY-10 354–385 85.56±0.81 60.76 31.59±1
11 GLY-11 321–361 83.26±0.66 58.75 33.45±1
12 GLY-12 311–320 92.47±1.12 61.16 38.15±2
GLY: Glyburide
Table 7: Percentage cumulative drug release data of glyburide nanosuspension
Time (H) Percentage cumulative drug release
GLY‑1 GLY‑2 GLY‑3 GLY‑4 GLY‑5 GLY‑6 GLY‑7 GLY‑8 GLY‑9 GLY‑10 GLY‑11 GLY‑12
0 0 0 0 0 0 0 0 0 0 0 0 0
1 18.26 15.8 13.44 10.22 17.55 15.22 13.22 8.22 18.22 15.25 13.85 10.43
2 31.52 22.84 23.54 19.52 28.65 24.65 25.36 18.65 34.25 24.65 20.65 24.36
3 49.55 38.41 35.41 28.47 40.01 35.65 34.58 24.15 50.22 34.22 28.69 32.84
4 61.2 55.74 42.68 37.85 59.14 48.52 47.26 30.17 68.24 47.15 35.01 40.21
5 78.55 69.14 54.21 46.24 72.36 60.2 55.3 39.98 79.25 56.84 42.59 48.65
6 88.49 80.14 68.11 57.15 88.24 78.52 65.84 45.21 89.22 61.47 50.22 57.1
7 – 99.16 78.1 65.85 99.28 86.21 74.22 52.02 – 75.26 65.64 65.95
8 – – 85.68 78.21 – 98.52 84.62 64.22 – 86.22 75.21 72.8
9 – – 97.02 85.25 – – 90.11 70.84 – 98.14 88.89 80.41
10 – – – 97.11 – – 99.45 81.58 – – 99.45 89.79
11 – – – – – – – 90.24 – – – 98.02
12 – – – – – – – 99.85 – – – –
GLY: Glyburide
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In vivo pharmacokinetic studies
Determination of GLY in rat K2 ethylenediaminetetraacetic acid 
plasma
Preparation of CC standards
The stock solutions ranging from 0.1 μg/ml to 1.0 μg/ml were prepared 
by diluting with mobile phase from main stock solution. Table 9 and 
Fig. 12 show CC data of GLY in rat plasma.
Evaluation of In vivo pharmacokinetic parameters
Based on in vitro drug release studies, GLY-8 formulation was 
selected for further in vivo pharmacokinetic characterization in rats. 
Plasma concentration of GLY in rats (1 mg/kg body weight [b.w.], 
p.o) is presented in the table. Table 10 summarizes the mean plasma 
concentration of GLY in rats (1 mg/kg b.w., p.o,) which was considered 
for computation of pharmacokinetic parameters. Figs. 13 and 14 show 
the representative chromatogram of GLY from plasma samples.
Cmax: Peak plasma concentration attained by GLY (GLY) was 
0.604±0.03μg/ml following per oral administration.
Tmax: Time required for attaining peak plasma concentration by GLY 
(GLY), following per oral administration, was 2±1.01 h.
Area under the curve (AUC): AUC (0-t) was calculated, and it was found to 
be 2.562±0.41 μg.h/ml for GLY. AUC (o-∞) was calculated, and it was found 
to be 2.147±0.45 μg/ml for GLY.
Fig. 5: Scanning electron microscopy photograph of glyburide‑8 
nanosuspension
Fig. 6: Differential scanning calorimetry thermogram of pure 
glyburide
Fig. 4: Fourier transformed infrared spectrum of glyburide plus 
polymer blend
Fig. 7: Differential scanning calorimetry thermogram of glyburide 
plus polymer blend
Fig. 8: Percentage cumulative drug release from glyburide 
nanosuspension
Fig. 9: Higuchi plot
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T1/2: Time required for a drug to decrease by half of its content was 
found to be 10.04 h following oral administration of GLY.
In vivo pharmacokinetic study of GLY-8 formulation in 6 rats following 
single oral administration of 1 mg/kg b.w. of GLY was performed. The 
concentration of drug in the plasma samples was obtained from the blood 
samples which were collected from each rat throughout a period of 12 h and 
were calculated. Fig. 14 shows the representative chromatogram of GLY from 
rat plasma. The concentration-time profile of GLY in the rat plasma is shown 
in Table 10. The mean estimated non-compartmental pharmacokinetic 
parameters derived from the plasma concentration profiles are summarized 
in Table 10, and Fig. 15 shows the mean plasma concentrations of GLY 
across the time points following per oral administration. GLY plasma 
concentrations calculated at different time intervals for 6 rats showed 
that the drug was readily absorbed after oral administration and the peak 
plasma concentration of GLY was reached by 2±1.01 h. The Cmax of GLY was 
0.604±0.03. The values of AUC (0-t) and AUC (0-∞) were found to be 2.562±0.41 
and 2.147±0.45 μg.h/ml, respectively. Till date, an extensive study of GLY 
pharmacokinetic parameters such as its distribution pattern, mechanism of 
metabolism, and excretion was not reported and still under investigation.
DISCUSSION
In the current work, an attempt has been made to introduce a new 
drug delivery system “nano particulates incorporated in suspension.” 
The mechanism of drug release from the nanosuspension release 
was explained in four steps. They are (1) Formulation of colloidal 
system, (2) size reduction to nanoparticles through homogenization, 
(3) counter diffusion mechanism of nano-sized particles into a 
suspension, and (4) sustained release of the drug and particle 
detachment.
Drug and excipient compatibility studies were performed using FTIR 
spectrophotometer and DSC, and no marked incompatibilities were 
found. GLY has been scanned in the UV spectrophotometer and found 
λmax at 229 nm. A CC was constructed in the concentration range of 
25–150 µg/ml. The curve was the best fit with R2 value of 0.9983 and 
slope of 0.0056. The FTIR spectra for pure drug of GLY and with blend 
are shown in Figs. 1 and 2. Furthermore, the GLY compatibility with 
polymer blend was proved by DSC. The DSC thermogram of GLY (Fig. 6) 
Table 8: Kinetic correlation coefficients and diffusion exponent data of various kinetic models of GLY nanosuspension
Formulation code Correlation coefficient values (R2) Diffusion exponent value (n)
Zero order Higuchi’s model Korsmeyer–Peppas First order
GLY-1 0.997841 0.965893 0.900845 −0.134 0.900766
GLY-2 0.997247 0.944732 0.980874 −0.13393 0.980738
GLY-3 0.998848 0.962434 0.9099 −0.10033 0.909931
GLY-4 0.9995 0.955341 0.978083 −0.09885 0.978057
GLY-5 0.99842 0.955166 0.921243 −0.12429 0.921226
GLY-6 0.998244 0.95406 0.927203 −0.11286 0.92719
GLY-7 0.996914 0.974591 0.874915 −0.08667 0.874964
GLY-8 0.997 0.950947 0.975553 −0.08486 0.975513
GLY-9 0.995607 0.970394 0.905735 −0.13314 0.905721
GLY-10 0.997745 0.964084 0.85161 −0.09417 0.851576
GLY-11 0.993451 0.94033 0.870733 −0.09121 0.870795
GLY-12 0.997648 0.97353 0.890978 −0.08182 0.890924
GLY: Glyburide
Table 9: CC data of GLY in rat plasma
Concentration (µg/ml) Peak area 1 Peak area 2 Peak area 3 Mean Peak area Standard Deviation % RSD
0.1 659782 652134 659423 657113 4315.68 0.66
0.2 1058864 1037138 1060168 1052057 12936.39 1.23
0.4 1313316 1330325 1326036 1323226 8845.90 0.67
0.6 1706481 1735033 1709901 1717138 15591.29 0.91
0.8 1950506 1941450 1940379 1944112 5563.49 0.29
1.0 2251880 2216008 2213456 2227115 21485.33 0.96
CC: Calibration curve, GLY: Glyburide
Table 10: Mean plasma concentration of GLY following oral 
administration














AUC(0-∞)  (µg.h/ml) 2.147±0.45
T1/2 (h) 10.04
GLY: Glyburide, Cmax: Maximum drug plasma concentration, Tmax: Time to reach 
maximum concentration, T1/2: Elimination half-life, MRT: Mean residence time, 
AUC: Area under the concentration-time curve
Fig. 10: Korsmeyer–Peppas plot
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reveals the melting point at 168.7°C, whereas GLY with blend (Figs. 6 
and 7) also shows the melting point at 168.0°C which proved that drug 
had good thermal stability. Nanosuspension formulation of GLY was 
prepared based on the principle of quasi emulsification solvent diffusion 
method. With increase in concentration of polymers, the prepared 
nanosuspension formulations had shown good correlation with size 
and particle charge (PVP, HPMC, and EDG RL 100). As the concentration 
of polymer increased, an increase in the entrapment efficiency was 
observed and average particle size also increased. GLY-8 was the best 
formulation with a particle size of 85–96 nm, 93.53% drug entrapment, 
and 90.26±1 mV of zeta potential. This formulation showed percentage 
drug release of 99.85 % in 24 h. The release exponents showed that 
value of “n” was 0.975513 (<1) indicating non-Fickian transport 
mechanism on drug release behavior. The drug relapse followed zero 
order with regression value near to 0.99 and diffusion type of release 
from the Higuchi equation regression value of 0.97.
In vivo pharmacokinetic study for optimized formulation (GLY-8) was 
carried out using the developed and validated reverse-phase high-
performance liquid chromatography method on Wistar albino rats. For 
GLY-8, Cmax and Tmax were found to be 0.604±0.03 μg/ml and 2±1.01 h, 
respectively. The values of t1/2 (h), AUC (0-t), and AUC (0-∞) were found to be 
10.04 h, 2.562±0.41 μg.h/ml, and 2.147±0.45 μg.h/ml respectively. Based 
on the obtained results, oral administration of nanosuspension could not 
only provide the better absorption of poorly water-soluble drugs but may 
also reduce toxicity and provide a new tool in drug delivery system.
Fig. 11: First‑order plot
Fig. 12: Calibration curve of glyburide in rat plasma
Fig. 13: Blank chromatogram from rat plasma sample
Fig. 14: Blank and Cmax chromatogram of glyburide from rat 
plasma sample
Fig. 15: Mean plasma concentration of glyburide in rat plasma
CONCLUSION
GLY is poorly water-soluble (BCS class II) drug. The poor aqueous 
solubility of this drug gives rise to many obstacles in the design 
of pharmaceutical formulations and leads to variable oral 
bioavailability. Hence, this drug was selected for the present study for 
enhancing their rate of dissolution and oral bioavailability through 
nanosuspension technologies. Nanosuspensions were prepared 
and evaluated by in vitro and in vivo methods. From the obtained 
results, it was concluded that all the nanosuspensions prepared 
were found to be fine and nano range. GLY was taken in phosphate 
buffer with a pH 7.4 at 229 nm, respectively, and nanosuspensions 
were prepared. The obtained nanosuspensions were checked for 
the characterization of size analysis, drug content, entrapment 
efficiency, drug release studies in in vitro, FTIR spectroscopy studies, 
DSC studies, and SEM studies. FTIR spectra showed no interactions 
between excipients and drug of the nanosuspension. Among all GLY 
nanosuspension formulations, GLY-8 formulation was considered 
as an optimized formulation which showed maximum drug release, 
i.e., 99.85% in 24 h.
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